

Drug	Sponsor	Stage	Mode of Action
MK8931	Merck	Phase 3	BACE Inhibitor
E2609	Biogen Idec	Phase 2	BACE Inhibitor
NIC5-15	Humanetics Pharmaceuticals	Phase 2	BACE Inhibitor
AZD3293	AstraZeneca & Lilly	Phase 2/3	BACE Inhibitor
CTS-21166	CoMentis	Phase 1	BACE Inhibitor
HPP854	High Point	Phase 1	BACE Inhibitor
PF-05297909	Pfizer	Phase 1	BACE Inhibitor
TAK-070	Takeda	Phase 1	BACE Inhibitor
VTP-37948	Vitae/Boeringer Ingelheim	Phase 1	BACE Inhibitor
Etazolate	ExonHit Therapeutics	Phase 2a	Alpha Secretase Activator
EGCg	Taiyo International	Phase 2/3	Alpha Secretase Activator
Scyllo-inositol	Transition Therapeutics	Phase 2	Alpha Secretase Activator
Begacestat	Pfizer	Phase 1	Gamma Secretase Inhibitor/Modulator
CHF 5074	CereSpir, Chiesi Pharmaceuticals	Phase 2	Gamma Secretase Inhibitor/Modulator
EVP-0962	EnVivo Pharmaceuticals	Phase 2	Gamma Secretase Inhibitor/Modulator
Atorvastatin	UBCH Clinic for Alzheimer's Disease	Phase 3	Gamma Secretase Inhibitor/Modulator
Simvastatin	Mount Sinai School of Medicine	Phase 3	Gamma Secretase Inhibitor/Modulator
Affitope AD02	Affris AG	Phase 2	Increased A β Clearance
Affitope AD03	Affris AG	Phase 1	Increased A β Clearance
Pioglitazone	Takeda/Eli Lilly	Phase 3	Decreased A β Production
Tramiprosate	McGill Center	Phase 3	Decreased A β Aggregation
PBT2	Prana Biotechnology	Phase 2	Decreased A β Aggregation
UB 311	United Biomedical, Inc.	Phase 1	A β Active Immunotherapy
V 950	Merck	Phase 1	A β Active Immunotherapy
CAD 106	Novartis	Phase 2	A β Active Immunotherapy
BAN2401	Biogen Idec	Phase 2	A β Active Immunotherapy
BIIB037	Biogen Idec	Phase 1	A β Active Immunotherapy
Ponezumab	Pfizer	Phase 2	A β Active Immunotherapy
Crenezumab	AC Immune/Genetech/Roche	Phase 2/3	A β Active Immunotherapy
Gantenerumab	Roche	Phase 3	A β Active Immunotherapy
Solanezumab	Eli Lilly	Phase 3	A β Active Immunotherapy
AAB-003	Janssen Pfizer	Phase 1	A β Active Immunotherapy
GSK933776	GlaxoSmithKline	Phase 1	A β Active Immunotherapy
SAR228810	Sanofi	Phase 1	A β Active Immunotherapy